Evaluation of FebriDx® for the management of children with acute febrile respiratory infection.

Autor: de la Matta Farrando P; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain., Suay Torres MT; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain., Sabater Sabate A; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain., Trenchs Sainz de la Maza V; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain; Influencia del entorno en el bienestar del niño y del adolescente, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Universidad de Barcelona, Barcelona, Spain. Electronic address: victoria.trenchs@sjd.es., Luaces Cubells C; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain; Influencia del entorno en el bienestar del niño y del adolescente, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Universidad de Barcelona, Barcelona, Spain., Hernández Bou S; Área de Urgencias, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain; Influencia del entorno en el bienestar del niño y del adolescente, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain; Enfermedades Infecciosas y Microbioma, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Enfermedades infecciosas y microbiologia clinica (English ed.) [Enferm Infecc Microbiol Clin (Engl Ed)] 2024 Jun-Jul; Vol. 42 (6), pp. 313-316. Date of Electronic Publication: 2024 Apr 30.
DOI: 10.1016/j.eimce.2024.04.002
Abstrakt: Introduction: Acute respiratory infections (ARI) are a common cause of inappropriate antibiotic prescription (ATB) in pediatrics. FebriDx® is a rapid diagnostic test that differentiates between viral and bacterial infections. The objective is to analyse the impact of FebriDx® on ATB prescription when managing febrile ARI.
Methods: Prospective study carried out in patients aged 1-<18 years with febrile ARI in the emergency department. FebriDx® was performed and the impact on management was evaluated at follow-up.
Results: A total of 216 patients were included. Clinical assessment and FebriDx® result coincided coincided in 174 (80.5%) cases. A modification of the initial therapeutic plan was made in 22 (52.4%) of the 42 discordant ones (10.2% of the overall patients). In pneumonia the impact was 34.5%; in all cases it involved not prescribing ATB.
Conclusions: FebriDx® could be a useful tool in the management of pediatric patients with febrile ARI to optimize ATB prescription.
(Copyright © 2024 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: